Edit
Collaborations Pharmaceuticals, Inc.
http://www.collaborationspharma.com/Last activity: 04.09.2024
Active
Our machine learning drug discovery and toxicology capabilities can be applied to rare & neglected disease research and consumer products testing
Location: United States, North Carolina
Employees: 11-50
Total raised: $2M
Founded date: 2015
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.09.2024 | Grant | $2M | - |
Mentions in press and media 13
| Date | Title | Description |
| 04.09.2024 | Collaborations Pharmaceuticals, Inc. Awarded over $2M Grant to develop Acetylcholinesterase Reactivators with Battelle | Collaborations Pharmaceuticals team photo 2024 Collaborations Pharmaceuticals logo NIEHS has awarded a $2,044,647 SBIR grant to Collaborations Pharmaceuticals, Inc. to develop new acetycholinesterase reactivators with Battelle RALEIGH, NC, ... |
| 08.07.2024 | Collaborations Pharmaceuticals, Inc., Invited to Participate in the Reckitt “The Science Inside Symposium 2024” | Collaborations Pharmaceuticals logo Reckitt The Science Inside Symposium 2024 The Science Inside symposium 2024 Collaborations Pharmaceuticals, Inc., are pleased to announce their invitation from Reckitt to participate in The Science Inside... |
| 11.04.2024 | Collaboration Leads to Repurposing an Existing Drug to Treat VX Poisoning | Collaborations Pharmaceuticals logo Collaborations Pharmaceuticals and Battelle published a new paper which demonstrated that an FDA approved drug may help in VX poisoning. RALEIGH, NORTH CAROLINA, USA, April 11, 2024 /EINPresswire.com/ -- ... |
| 11.04.2024 | Collaborations Pharmaceuticals, Inc. Introduce Batten Disease CLN1 Registry In Order to Find Patients | Collaborations Pharmaceuticals logo A logo for a CLN1 (Batten disease) registry Collaborations Pharmaceuticals, Inc. has developed a registry for Batten Disease CLN1 In order to find patients with this rare disease and gather information. R... |
| 02.09.2022 | Collaborations Pharmaceuticals, Inc. and The University of Arizona Awarded A Phase II STTR award from NIGMS/NIH | Collaborations Pharmaceuticals logo Headshot of Dr. Stephen Wright and Dr. Nathan Cherrington New $1,729,532.72 grant awarded to Collaborations Pharmaceuticals, Inc. (CPI) and the University of Arizona to develop MegaTrans machine learning ... |
| 01.09.2022 | Collaborations Pharmaceuticals, Inc. and collaborators announce publication on the efficacy of a treatment for CLN1 | Collaborations Pharmaceuticals logo Collaborations Pharmaceuticals, Inc staff A new paper published in the Journal of Clinical Investigation describes the efficacy of an enzyme replacement therapy in multiple species for Batten disease. RAL... |
| 01.08.2022 | Collaborations Pharmaceuticals, Inc. Awarded A Phase II SBIR award from NIEHS/NIH to Develop MegaTox® software | Collaborations Pharmaceuticals logo MegaTox logo RALEIGH, NC, USA, August 1, 2022 /EINPresswire.com/ -- The National Institute of Environmental Health Sciences (NIEHS) has awarded $1,710,006 to Collaborations Pharmaceuticals, Inc. (CPI) to ... |
| 09.06.2022 | Collaborations Pharmaceuticals, Inc. Awarded A Phase II SBIR From NIH/NINDS To Develop Batten Disease Treatment | Collaborations Pharmaceuticals, Inc staff Collaborations Pharmaceuticals logo A Phase II SBIR awarded to Collaborations Pharmaceuticals, Inc. by the National Institutes of Health / National Institute of Neurological Disorders and Stroke. Wh... |
| 27.05.2022 | Collaborations Pharmaceuticals, Inc. Announces Publication on Generative Molecule Design Software MegaSyn | Generative molecule design using MegaSyn Collaborations Pharmaceuticals logo Collaborations Pharmaceuticals, Inc. announces the publication of a paper detailing their generative molecule design software, MegaSyn. MegaSyn is the latest AI-ba... |
| 25.05.2022 | Global Collaboration Demonstrates Pyronaridine is Active Against COVID-19 in an Animal Model | Effects of pyronaridine treatment in mice infected with SARS-CoV-2 Collaborations Pharmaceuticals, Inc. and international collaborators publish paper on pyronaridine and its protection against infection with SARS-CoV-2 COVID-19 continues to... |
Show more